Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON49992
NL-OMON49992
Recruiting
Not Applicable

Target to B! - Towards patient-tailored immunotherapy to effectively treat B-cell associated disease - T2B!

Academisch Medisch Centrum0 sites2,000 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionshematologische aandoeningenB-cell related disordersB-cell mediated immunological or oncological disorders10003816

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
hematologische aandoeningen
Sponsor
Academisch Medisch Centrum
Enrollment
2000
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\) subjects with a clinical syndrome fulfilling the diagnostic criteria for
  • •pre\-specified B\-cell\-related diseases; 2\) disease severity requiring start of
  • •anti\-CD20 or antibody targeted therapy and 3\) adults or children above the age
  • •of 5 years.

Exclusion Criteria

  • •1\) anti\-CD20 treatment or thymectomy as part of clinical care, within the last
  • •9 months ; 2\) plasma exchange, plasmapheresis or immunoadsorption within the
  • •last 3 months ; 3\) change in the dose of general immunosuppressive or
  • •oncological drugs, including azathioprine, mycophenolate mofetil, ciclosporin,
  • •tacrolimus within the last 3 months (change in dose of corticosteroids or
  • •intravenous immunoglobulin dose allowed); 4\) anti\-CD20 treatment or antibody
  • •depleting therapy as part of clinical trials as based on case\-based peer review
  • •between researchers

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging.NSCLCskin cancer (melanoma)10027476
NL-OMON51740niversitair Medisch Centrum Groningen200
Unknown
Not Applicable
Feasibility 'innate' allogeneic stem cells transplantioHematological malignancies (hematologische maligniteiten)Allogeneic stem cells transplantation (allogene stamcel transplantatie)Innate immune system (aangeboren immuunsysteem)
NL-OMON25484MC UtrechtHeidelberglaan 1003584 CX Utrecht35
Completed
Not Applicable
Development of a personalized immune-modulating therapy for patients with atopic dermatitis: evaluation of clinical efficacy of autologous immunoglobulin therapy for atopic dermatitis: a randomized, double-blind, placebo-controlled studyDiseases of the skin and subcutaneous tissue
KCT0001597Ajou University Hospital51
Not yet recruiting
Not Applicable
To successfully develop novel ways of identifying Indian patients that are likely to benefit from immunotherapy for lung cancer
CTRI/2022/05/042559Emory Vaccine Centre
Not yet recruiting
Phase 1
A Clinical Trial to Evaluate the Effects of Autologous induced Pluripotent Stem Cell-Derived Natural Killer Cells in Personalized Treatment of Patients with Advanced Metastatic Breast CancerAdvanced Breast Cancer.Malignant neoplasm of breast
IRCT20200429047241N1International Center for Personalized Medicine (ICPM)32